Patents Examined by Amy Bowman
  • Oral delivery of therapeutically effective LNA oligonucleotides
    Patent number: 9566293
    Abstract: The invention provides for LNA oligomers, for the treatment of a metabolic or liver disorder, wherein the LNA oligomer is administered orally in a unit dose of less than 50 mgs/kg, wherein the LNA oligomer is administered in the presence of a penetration (permeation) enhancer.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: February 14, 2017
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Gregroy Hardee, Ellen Marie Straarup, Marie Wickstrom Lindholm, Henrik Orum, Henrik Frydenlund Hansen
  • RNA interference mediating small RNA molecules
    Patent number: 9567582
    Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: February 14, 2017
    Assignees: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, WHITEHEAD INSTITUTE OF BIOMEDICAL TECHNOLOGY, UNIVERSITY OF MASSACHUSETTS
    Inventors: Thomas Tuschl, Sayda Mahgoub Elbashir, Winfried Lendeckel
  • Medical devices
    Patent number: 9561311
    Abstract: Medical devices comprising an anti-connexin agent suitable for introduction into a subject.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: February 7, 2017
    Assignee: CoDA Therapeutics, Inc.
    Inventors: David Lawrence Becker, Colin Richard Green, Bradford James Duft
  • Transferrin/transferrin receptor-mediated siRNA delivery
    Patent number: 9562230
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: February 7, 2017
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Jon E. Chatterton, Abbot F. Clark
  • gene in cancer and inflammation
    Patent number: 9556437
    Abstract: The present invention demonstrates for the first time that FAT1 plays an important role in modulating PDCD4 expression, which in turn regulates AP-1 dependent transcription, controls processes crucial for migration and invasion in cancer cells, controls induction of a pro-inflammatory micro environment in cancer cells. The study illustrates a link between inflammation and cancer in cells or in a subject. This work highlights the importance of FAT1 in the induction of the cellular pathways of migration and invasion, proteolysis of the ECM and the expression of pro-inflammatory molecules leading to a favorable micro environment for tumor and cancer progression.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: January 31, 2017
    Assignees: DEPARTMENT OF BIOTECHNOLOGY (DBT), ALL INDIA INSTITUTE OF MEDIAL SCIENCES (AIIMS), NATIONAL BRAIN RESEARCH CENTRE (NBRC)
    Inventors: Kunzang Chosdol, Bhawana Dikshit, Subrata Sinha
  • Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery
    Patent number: 9555060
    Abstract: Some embodiments comprise methods, systems, and compositions to produce and/or administer modified exosomes or other vesicles containing one or more selected microRNAs, including but not limited to, miR-146b. Some embodiments also comprise the therapeutic administration and use of such modified exosomes and/or producer cells to treat mammalian injuries and diseases, including in human beings.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: January 31, 2017
    Assignee: Henry Ford Health System
    Inventors: Mark E. Katakowski, Benjamin A. L. Buller, Michael Chopp
  • Targeting microRNAs for the treatment of fibrosis
    Patent number: 9556435
    Abstract: Provided herein are compositions and methods for the modulation of miR-214 for the treatment and/or prevention of fibrosis and fibroproliferative conditions.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: January 31, 2017
    Assignee: Regulus Therapeutics Inc.
    Inventor: B. Nelson Chau
  • Riboregulator compositions and methods of use
    Patent number: 9550987
    Abstract: The invention provides novel and versatile classes of riboregulators, including inter alia activating and repressing riboregulators, switches, and trigger and sink RNA, and methods of their use for detecting RNAs in a sample such as a well and in modulating protein synthesis and expression.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: January 24, 2017
    Assignees: President and Fellows of Harvard College, Trustees of Boston University
    Inventors: Alexander A. Green, Peng Yin, James J. Collins
  • Identification of novel genes coding for small temporal RNAs
    Patent number: 9550993
    Abstract: In Caenorhabditis elegans, lin-4 and let-7 enclode 22- and 21-nucleotide RNAs, respectively, that function as key regulators of developmental timing. Because the appearance of these short RNAs is regulated during development, they are also referred to as “small temporal RNAs” (stRNAs). We show that many more 21- and 22-nt expressed RNAs, termed microRNAs, (miRNAs), exist in invertebrates and vertebrates, and that some of these novel RNAs, similar to let-7 stRAN, are also highly conserved. This suggests that sequence-specific post-transcriptional regulatory mechanisms mediated by small RNAs are more general than previously appreciated.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: January 24, 2017
    Assignee: Max-Planck Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Thomas Tuschl, Mariana Lagos-Quintana, Winfried Lendeckel, Jutta Dammann, Reinhard Rauhut
  • RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
    Patent number: 9550994
    Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: January 24, 2017
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt, Jon E Chatterton
  • Rational design of microRNA-siRNA chimeras for multi-functional target suppression
    Patent number: 9550989
    Abstract: The present disclosure encompasses methods for rational design of microRNA and small interfering RNA chimeras and compositions and methods of use thereof.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: January 24, 2017
    Assignee: WASHINGTON UNIVERSITY
    Inventor: Xiaowei Wang
  • Methods of inhibiting cancer stem cells with HMGA1 inhibitors
    Patent number: 9545417
    Abstract: The presently disclosed subject matter relates to methods of inhibiting cancer stem cells and growth of aggressive and/or poorly differentiated metastatic tumors comprising the cancer stem cells with HMGA1 inhibitors. The presently disclosed subject matter also provides methods of selecting and treating a subject with aggressive and/or poorly differentiated metastatic cancer using HMGA1 inhibitors.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: January 17, 2017
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Linda M. Smith Resar, David Huso, Leslie Cope
  • Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
    Patent number: 9540645
    Abstract: The present invention concerns methods and compositions for diagnosing and/or treating vascular diseases including cancer, cardiac diseases, vascular diseases of the eye, and inflammatory diseases. The methods involve measuring the levels of one or multiple miRNAs in patient samples and using the test results to diagnose and/or predict an optimal treatment regimen for the patient. Compositions described in the invention include nucleic acids that function as miRNAs or miRNA inhibitors that can be introduced to a patient to reduce or increase vascularization as needed.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: January 10, 2017
    Assignees: The John Hopkins University, ASURAGEN, Inc.
    Inventors: Jikui Shen, Kevin Kelnar, Jeffrey Shelton, David Brown, Peter Campochiaro
  • MiRNAs as novel therapeutic targets and diagnostic biomarkers for parkinsons disease
    Patent number: 9540692
    Abstract: The disclosure provides pharmaceutical compositions including an oligonucleotide that down-regulates the over-expression of at least one miRNA of SEQ ID NOs: 1-283. The oligonucleotide may be complementary to the nucleotide sequence of at least one of SEQ ID NOs: 1-283, or hybridizes under stringent conditions to a nucleotide sequence of at least one of SEQ ID NOs: 1-283. Further provided are methods of diagnosing Parkinson's Disease (PD) in a subject. The methods may include detecting the level of expression of at least one miRNA of SEQ ID NOs: 1-283 in a biological sample from the subject, and comparing the level of expression in the sample to the level of expression in a reference. Further provided are methods for treating, preventing, or reducing the risk of PD. Kits are also provided.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: January 10, 2017
    Assignee: Rush University Medical Center
    Inventor: Shunbin Xu
  • Methods of treating vascular inflammatory disorders
    Patent number: 9534219
    Abstract: Provided are methods of treating or delaying the onset of a vascular inflammatory disease (e.g., acute lung injury) in a subject including administering to the subject a therapeutically effective amount of a nucleic acid containing all or a part of the sequence of mature miR-181b (SEQ ID NO: 1). Also provided are methods of decreasing nuclear factor-?? (NF-??) signaling in an endothelial cell including administering to the subject a nucleic acid containing all or a part of the sequence of mature miR-181b (SEQ ID NO: 1).
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: January 3, 2017
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Mark W. Feinberg, Xinghui Sun
  • Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family
    Patent number: 9533004
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Dystrophin family, in particular, by targeting natural antisense polynucleotides of Dystrophin family. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DMD family.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: January 3, 2017
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Peptide-based in vivo siRNA delivery system
    Patent number: 9526796
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: December 27, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: David B Rozema, Darren H Wakefield
  • Low density lipoprotein receptor-mediated siRNA delivery
    Patent number: 9526799
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: December 27, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventor: Jon E. Chatterton
  • Composition and method for treating a hematological malignancy
    Patent number: 9518300
    Abstract: Provided are compositions and methods for treating hematological malignancies, such as multiple myeloma, in a subject by increasing levels or activity of miR-30 RNA in plasma cells of the subject.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: December 13, 2016
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Ruben Carrasco, Jianjun Zhao
  • Pharmaceutical composition comprising Nanog shRNA, and method of using Nanog shRNA to treat cancer
    Patent number: 9512429
    Abstract: The present description relates to an inhibitory RNA molecule, comprising an oligonucleotide that selectively knocks down expression a Nanog pseudogene expressed in many human cancers, a replicating viral vector capable of encoding such inhibitory RNA molecule, pharmaceutical compositions comprising said vector, and methods of treating cancer by administration of said pharmaceutical composition.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: December 6, 2016
    Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: John Milburn Jessup, Nikolay Korokhov